Bothell’s Seattle Genetics announces deal to manufacture tumor drug

Published 1:30 am Friday, February 10, 2017

Bothell biotech firm Seattle Genetics announced a development and license agreement with Immunomedics, Inc. under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize an antibody-drug conjugate that can target tumors including cancers of the breast, lung and bladder.